Kunpoong Bio Co.

Jeju, South Korea

Kunpoong Bio Co.

Jeju, South Korea
Time filter
Source Type

News Article | November 2, 2016
Site: www.newsmaker.com.au

Chitin is a naturally found polymer of N-acetyl glucosamine. Chitin forms a major constituent of fungi cell walls, arthropods exoskeletons and beaks and internal shells of marine animals. Chitin can be segmented based on its derivatives such as glucosamine, chitosan and others. End user applications of chitin include agrochemicals, food & beverages, biotechnology, pulp & paper, healthcare & medicine, photography products, cosmetics, textile finishes among others. Growing end user applications and surging demand from agrochemicals and healthcare sectors are expected to drive the chitin market. Chitin is a biopolymer and its fat trapping property makes it indispensable to use in healthcare sector. It is claimed to reduce absorption of lipids and fats into body and therefore it is always recommended in weight management program. Chitin is also used to treat bowel syndrome, as this biopolymer has cleansing activities to facilitate better digestion, hence it is also used in dietary supplements and in blood pressure management. Further, growing demand for chitins and its derivatives from water treatment sector is expected to boost the market growth. Need for replacement of synthetic flocculants is aiding the demand for biopolymers. Chitin is used as coagulant, filtration agent for spas and pools, removal of metal ions, treatment of nuclear waste water and de-colorization of dye water and industrial waste treatments. In addition, growing demand from food & beverages industry is expected to further fuel the market growth. Chitin is used as a food preservative to protect cooked food from oxidation and bacterial growth. For example, it is being used to preserve beef and turkey as it significantly decreases bacterial outgrowth during the chilling process. It also stabilizes the food content at high temperature. Additionally,growing demand from other end user industries such as textile, paper & pulp, photography and cosmetics is expected to fuel the market growth. Among end user industries, healthcare and food & beverages are expected to grow at higher pace as compared to others. However high production cost, lack of quality product and low production capacities are expected to hamper the market growth. Applications like food and cosmetics require high purity products as it has to get FDA approval for use in formulations. Lack of production technology, lack of awareness about benefits of biopolymers and high patent costs may inhibit the chitin market growth. New applications in field of biomedicine and agrochemicals are poised to fuel future chitin consumption. Asia Pacific was the largest market of the chitin in terms of consumption. Growing demand from various end user applications are expected to drive the market in this region. Increasing health awareness coupled with growing cholesterol related problem has increased the demand for chitin. This region is expected to grow at higher pace as compared to other regions. Asia Pacific was followed by North America in terms of consumption. Application in biomedicine and cosmetics are expected to fuel the market in this region. Developing countries from Latin America and Middle East are expected to provide opportunities in the near future. Some of key players include Navamedic ASA,Biothera,Kunpoong Bio Co. Ltd., CarboMer Inc., Advanced Biopolymers AS, Sonat Co.,Heppe Medical Chitosan GmbH, United Chitotechnologies Inc., Dalian Xindie Chitin Co. Ltd., Meron Biopolymers, QBas Co., PrimexEhf, TaizhouCandorly Sea Biochemical & Health Products Co. Ltd. among others. This research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data and statistically-supported and industry-validated market data and projections with a suitable set of assumptions and methodology. It provides analysis and information by categories such as market segments, regions, product types and distribution channels.

Kim H.J.,Yonsei University | Ahn H.Y.,Yonsei University | Kwak J.H.,Yonsei University | Shin D.Y.,Yonsei University | And 3 more authors.
Food and Function | Year: 2014

We aimed to evaluate the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. This study was a randomized, double-blind, placebo-controlled clinical trial. Subjects with prediabetes were randomly assigned to the GO2KA1 intervention group or the placebo group for 12 weeks. We assessed the serum levels of glucose, insulin, and C-peptide by a 2 hour value in the 75 g oral glucose tolerance test (OGTT), HbA1c, pro-inflammatory cytokines, and plasma adiponectin at baseline and after the 12 week intervention. The treatment group showed a significant decrease in the serum glucose level at 30 min (p = 0.013) and at 60 min (p = 0.028). The change of the serum glucose level at 60 min was significant in the treatment group compared with the placebo group (p = 0.030). Also, the plasma level of HbA1c (p = 0.023) and the pro-inflammatory cytokines (IL-6 and TNF-α) were reduced and plasma adiponectin was increased in the GO2KA1 intervention group after the 12 week treatment. However, the placebo group did not show any significant changes in these biomarkers. In subjects with prediabetes, 12 week supplement with GO2KA1 may help control postprandial glucose compared with control. © 2014 the Partner Organisations.

Jo S.-H.,Hannam University | Ha K.-S.,Hannam University | Moon K.-S.,Korea Institute of Toxicology | Kim J.-G.,Kunpoong Bio Co. | And 4 more authors.
International Journal of Molecular Sciences | Year: 2013

This research investigated the effect of enzymatically digested low molecular weight (MW) chitosan oligosaccharide on type 2 diabetes prevention. Three different chitosan oligosaccharide samples with varying MW were evaluated in vitro for inhibition of rat small intestinal α-glucosidase and porcine pancreatic α-amylase (GO2KA1; <1000 Da, GO2KA2; 1000-10,000 Da, GO2KA3; MW > 10,000 Da). The in vitro results showed that all tested samples had similar rat α-glucosidase inhibitory and porcine α-amylase inhibitory activity. Based on these observations, we decided to further investigate the effect of all three samples at a dose of 0.1 g/kg, on reducing postprandial blood glucose levels in Sprague-Dawley (SD) rat model after sucrose loading test. In the animal trial, all tested samples had postprandial blood glucose reduction effect, when compared to control, however GO2KA1 supplementation had the strongest effect. The glucose peak (Cmax) for GO2KA1 and control was 152 mg/dL and 193 mg/dL, respectively. The area under the blood glucose-time curve (AUC) for GO2KA1 and control was 262 h mg/dL and 305 h mg/dL, respectively. Furthermore, the time of peak plasma concentration of blood glucose (Tmax) for GO2KA1 was significantly delayed (0.9 h) compared to control (0.5 h). These results suggest that GO2KA1 could have a beneficial effect for blood glucose management relevant to diabetes prevention in normal and pre-diabetic individuals. The suggested mechanism of action is via inhibition of the carbohydrate hydrolysis enzyme α-glucosidase and since GO2KA1 (MW < 1000 Da) had higher in vivo effect, we hypothesize that it is more readily absorbed and might exert further biological effect once it is absorbed in the blood stream, relevant to blood glucose management. © 2013 by the authors; licensee MDPI, Basel, Switzerland.

Kim J.-G.,Kunpoong Bio Co. | Jo S.-H.,Hannam University | Ha K.-S.,Hannam University | Kim S.-C.,Kunpoong Bio Co. | And 3 more authors.
BMC Complementary and Alternative Medicine | Year: 2014

Background: Type 2 diabetes is a serious problem for developed countries. Prevention of prediabetes progression to type 2 diabetes with the use of natural products appears to a cost-effective solution. Previously we showed that enzymatically digested low molecular weight chitosan-oligosaccharide with molecular weight (MW) below 1,000 Da (GO2KA1) has potential for hyperglycemia management.Methods: In this study we evaluated the effect of long-term supplementation of GO2KA1 on hyperglycemia using a db/db mice model. Additionally, we evaluated the effect of GO2KA1 on sucrase and glucoamylase activities and expression, using the same db/db mice model.Results: After 42 days we observed that GO2KA1 supplementation reduced both the blood glucose level and HbA1c in a similar manner with a known anti-diabetic drug, acarbose. When the sucrase and glucoamylase activities of GO2KA1 and control mice were evaluated using enzymatic assay, we observed that GO2KA1 significantly inhibited sucrase in all 3 parts of the intestine, while glucoamylase activity was significantly reduced only in the middle and lower part. When the sucrase-isomaltase (SI) complex expression on mRNA level was evaluated, we observed that GO2KA1 had minimal inhibitory effect on the upper part, more pronounced inhibitory effect on the middle part, while the highest inhibition was observed on the lower part. Our findings suggest that long-term GO2KA1 supplementation in db/db mice results to significant blood glucose and HbA1c reduction, to levels similar with those of acarbose. Furthermore, our findings confirm previous in vitro observations that GO2KA1 has inhibitory effect on carbohydrate hydrolysis enzymes, namely sucrase, maltase and SI complex.Conclusions: Results from this study provide a strong rationale for the use of GO2KA1 for type 2 diabetes prevention, via inhibition of carbohydrate hydrolysis enzymes. Based on the findings of this animal trial, clinical trials will be designed and pursued. © 2014 Kim et al.; licensee BioMed Central Ltd.

Jo S.-H.,Hannam University | Ha K.-S.,Hannam University | Lee J.-W.,Kunpoong Bio Co. | Kim Y.-C.,University of Massachusetts Amherst | And 2 more authors.
Food Science and Biotechnology | Year: 2014

The effects of chitosan-oligosaccharide (GO2KA1) on postprandial blood glucose levels in adults with normal blood glucose levels were investigated. Postprandial blood glucose levels were measured at 30, 60, 90, and 120 min after sucrose administration with and without 500 mg of GO2KA1. GO2KA1 administration reduced the area under the blood glucose-time curve (AUC) and the blood glucose peak (Cmax) values while the time of peak plasma concentration of blood glucose (Tmax) value was significantly (p<0.05) increased, compared to controls. GO2KA1 reduced postprandial blood glucose level increases via slower absorption of glucose in the small intestine based on carbohydrate hydrolyzing enzyme inhibition. © 2014 The Korean Society of Food Science and Technology and Springer Science+Business Media Dordrecht.

Yang E.-J.,Jeju Biodiversity Research Institute | Kim J.-G.,Kunpoong Bio Co. | Kim J.-Y.,Jeju Biodiversity Research Institute | Kim S.C.,Kunpoong Bio Co. | And 3 more authors.
Central European Journal of Biology | Year: 2010

We examined the effects of chitosan oligosaccharides (COSs) with different molecular weights (COS-A, 10 kDa < MW < 20 kDa; COS-C, 1 kDa < MW < 3 kDa) on the lipopolysaccharide (LPS)-induced production of prostaglandin E2 and nitric oxide and on the expression of cyclooxygenase-2 and inducible nitric oxide synthase in RAW264.7 macrophages. COS-A (0.4%) and COS-C (0.2%) significantly inhibited PGE2 production in LPS-stimulated macrophages without cytotoxicity. The effect of COS-A and COS-C on COX-2 expression in activated macrophages was also investigated by immunoblotting. The inhibition of PGE2 by COS-A and COS-C can be attributed to the blocking of COX-2 protein expression. COS-A (0.4%) and COS-C (0.2%) also markedly inhibited the LPS-induced NO production of RAW 264.7 cells by 50.2% and 44.1%, respectively. The inhibition of NO by COSs was consistent with decreases in inducible nitric oxide synthase (iNOS) protein expression. To test the inhibitory effects of COS-A and COS-C on other cytokines, we also performed ELISA assays for IL-1β in LPS-stimulated RAW 264.7 macrophage cells, but only a dose-dependent decrease in the IL-1β production exerted by COS-A was observed. In order to test for irritation and the potential sensitization of COS-A and COS-C for use as cosmetic materials, human skin primary irritation tests were performed on 32 volunteers; no adverse reactions of COSs usage were observed. Based on these results, we suggest that COS-A and COS-C be considered possible anti-inflammatory candidates for topical application. © Versita Warsaw and Springer-Verlag Berlin Heidelberg.

Disclosed is a method for preparation of a chitosan oligosaccharide composition capable of increasing a content of disaccharide in chitosan oligosaccharide with excellent effects of reducing HbAlc and blood glucose as well as excellent thermal stability. The method for preparation of a chitosan oligosaccharide composition includes: adding chitosan to distilled water to swell the chitosan; firstly treating the chitosan with a chitosanase to prevent the chitosan solution from becoming a state of being viscose, then, adding an organic acid to a mixed solution of the chitosan and chitosanase at a predetermined time interval bit by bit over several additions; allowing mutual reaction between the chitosan, chitosanase and organic acid; and inactivating the chitosanase to obtain the chitosan oligosaccharide composition. Further, a medicine and/or health supplement food which is effective in preventing and treating diabetes, including at least 40% of disaccharide without monosaccharide, is also disclosed.

Kunpoong Bio Co. | Date: 2013-08-23

Pharmaceutical preparations; dietetic substances adapted for medical use, dietary supplement.

Kunpoong Bio Co. | Date: 2010-10-09

Pharmaceutical preparations for the prevention and management of type two diabetes, Dietetic foods adapted for medical use, dietary supplements.

Kunpoong Bio Co. | Date: 2012-06-19

Pharmaceutical preparations for immune system health, Dietetic foods adapted for medical use, dietary supplements.

Loading Kunpoong Bio Co. collaborators
Loading Kunpoong Bio Co. collaborators